A randomized trial found that delivering Alzheimer’s genetic and blood-biomarker results through a patient-controlled digital platform was no worse than a clinician-led telehealth visit for patient anxiety, distress, and knowledge, researchers reported at the Clinical Trials on Alzheimer’s Disease conference in Boston and in JAMA Neurology.
The findings address a direct consequence of the 21st Century Cures Act, which requires most test results to appear in patient portals immediately — often before a clinician can explain them. "We found that learning Alzheimer’s genetic and biomarker information from a digital platform is no less effective — in other words, no worse than — receiving this information from a clinician telehealth visit," said Jessica Langbaum, PhD, of the Banner Alzheimer’s Institute in Phoenix, who presented the data.
The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) trial randomized 666 participants ages 60 to 80 in a 2:1 ratio to receive APOE genotype results via a digital platform (435 participants) or a genetic counselor via telehealth (216 participants), JAMA Neurology reported. Participants had a mean age of 68, a mean Montreal Cognitive Assessment score of 19, and 67% were women, according to JAMA Neurology.
The digital arm used a secure web portal or an SMS-based chat option that included optional personalized risk estimates for developing mild cognitive impairment or dementia by age 85. Participants could request clinician assistance before, after, or instead of digital disclosure.
Six months later, participants were offered plasma phosphorylated tau 217 (p-tau217) results through the same assigned method, with a study physician communicating results in the telehealth group. Blood samples were analyzed with a research-use-only assay classifying results as negative, intermediate, or positive.

One to seven days after APOE disclosure, the two arms showed no overall differences in Alzheimer’s-related knowledge, anxiety symptoms, or disease-specific distress, Langbaum said.
Among APOE ε4 carriers, three small, non-persistent differences emerged: greater reduction in disease-specific distress in the telehealth arm, a higher mean negative response to learning genetic risk in the digital arm, and slightly higher satisfaction with telehealth — though satisfaction was high in both groups. No significant differences appeared among noncarriers, who rated telehealth sessions more favorably.
Digital disclosure was associated with slightly higher negative responses to learning genetic risk, but the differences were small, unlikely to be clinically significant, and did not persist longitudinally, JAMA Neurology reported. The study team envisions the platform plugging into patient portals to help patients understand and contextualize results as biomarkers such as p-tau217 move toward clinical use.
The study was published online November 18 in JAMA Neurology.
What the eSMARTER Trial Measured
| Outcome | Digital Disclosure (n=435) | Telehealth Disclosure (n=216) | Noninferiority Met? |
|---|---|---|---|
| Anxiety (1–7 days) | No overall difference | No overall difference | Yes |
| Disease-specific distress (1–7 days) | No overall difference | Greater reduction in ε4 carriers | Yes (overall) |
| Alzheimer’s knowledge (1–7 days) | No overall difference | No overall difference | Yes |
| Satisfaction (1–7 days) | High | Slightly higher in ε4 carriers | — |
21st Century Cures Act impacts patient portal results
What is the 21st Century Cures Act and why does it matter here?
“This is important given that most patients learn their test results from a report in their patient portal — often a static report or PDF, with limited to no additional information or context about their results and what they mean — and have to wait until their scheduled follow-up appointment to speak with their clinician,” Jessica Langbaum, PhD, of the Banner Alzheimer's Institute in Phoenix, said. That means patients can see Alzheimer’s genetic and biomarker results before a clinician contacts them, creating a need for scalable, supportive digital disclosure tools.
How did the digital platform work?
Participants accessed a secure website or an SMS-based chat that presented results with optional educational modules and personalized risk estimates. They could request a clinician at any point before, during, or after viewing results.
Were there any safety concerns?
No. Overall anxiety, distress, and knowledge scores were equivalent between arms. Small, transient differences in distress and negative emotional response appeared only among APOE ε4 carriers and did not persist at follow-up.
What is p-tau217?
Phosphorylated tau 217 is a blood-based biomarker that indicates Alzheimer’s disease pathology. In the trial, results were classified as negative, intermediate, or positive using a research-use-only assay.
Jessica Langbaum, PhD, of the Banner Alzheimer’s Institute in Phoenix, was not involved in Biogen’s study of the experimental tau-targeting drug diranersen but commented on its potential at the Alzheimer’s Association International Conference in London. She described the findings as “really quite promising if it were to hold up” in larger testing, while noting “This is early days.”
Can health systems adopt this platform now?
The researchers said the platform is designed to integrate with existing patient portals, but the trial used a study-specific build.
Related reading